Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.38 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL4161893 | 0.89 | BRD4 (0.43) | BRD4IKBKBCHUKPIP4K2APIP4K2B | |
| Propionic Acid SCHEMBL4158106 | 0.87 | BRD4 (0.60) | BRD4 | |
| Propionic Acid SCHEMBL4166965 | 0.86 | BRD4 (0.41) | BRD4 | |
| Propionic Acid SCHEMBL4155591 | 0.86 | BRD4 (0.50) | BRD4 | |
| Propionic Acid SCHEMBL4157617 | 0.86 | BRD4 (0.64) | BRD4 | |
| Propionic Acid SCHEMBL4168329 | 0.85 | BRD4 (0.40) | BRD4 | |
| Propionic Acid SCHEMBL4159957 | 0.85 | BRD4 (0.49) | BRD4 | |
| Propionic Acid SCHEMBL4169897 | 0.85 | BRD4 (0.59) | BRD4 | |
| Propionic Acid SCHEMBL4155599 | 0.85 | BRD4 (0.49) | BRD4 | |
| Propionic Acid SCHEMBL3246304 | 0.84 | KDM4E (0.51) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | BRD4 545/4885MMP2 1886/4885MMP13 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.